471 related articles for article (PubMed ID: 34630112)
1. Molecular Basis of Prostate Cancer and Natural Products as Potential Chemotherapeutic and Chemopreventive Agents.
Bai B; Chen Q; Jing R; He X; Wang H; Ban Y; Ye Q; Xu W; Zheng C
Front Pharmacol; 2021; 12():738235. PubMed ID: 34630112
[TBL] [Abstract][Full Text] [Related]
2. Target to apoptosis: a hopeful weapon for prostate cancer.
Tang DG; Porter AT
Prostate; 1997 Sep; 32(4):284-93. PubMed ID: 9288188
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. Bioactive natural products for chemoprevention and treatment of castration-resistant prostate cancer.
Kallifatidis G; Hoy JJ; Lokeshwar BL
Semin Cancer Biol; 2016 Oct; 40-41():160-169. PubMed ID: 27370570
[TBL] [Abstract][Full Text] [Related]
5. Natural compounds with anti-ageing activity.
Argyropoulou A; Aligiannis N; Trougakos IP; Skaltsounis AL
Nat Prod Rep; 2013 Oct; 30(11):1412-37. PubMed ID: 24056714
[TBL] [Abstract][Full Text] [Related]
6. Suppressive Effect and Molecular Mechanism of
Subhawa S; Naiki-Ito A; Kato H; Naiki T; Komura M; Nagano-Matsuo A; Yeewa R; Inaguma S; Chewonarin T; Banjerdpongchai R; Takahashi S
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298624
[No Abstract] [Full Text] [Related]
7. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
8. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
Damodaran S; Lang JM; Jarrard DF
J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
[TBL] [Abstract][Full Text] [Related]
9. Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer.
Cicero AFG; Allkanjari O; Busetto GM; Cai T; Larganà G; Magri V; Perletti G; Robustelli Della Cuna FS; Russo GI; Stamatiou K; Trinchieri A; Vitalone A
Arch Ital Urol Androl; 2019 Oct; 91(3):. PubMed ID: 31577095
[TBL] [Abstract][Full Text] [Related]
10. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Fallah J; Zhang L; Amatya A; Gong Y; King-Kallimanis B; Bhatnagar V; Weinstock C; Suzman DL; Agrawal S; Chang E; Anscher MS; Chi DC; Xu JX; Brewer JR; Brave MH; Hadadi M; Theoret MR; Kluetz PG; Goldberg KB; Ibrahim A; Tang S; Pazdur R; Beaver JA; Amiri-Kordestani L; Singh H
Lancet Oncol; 2021 Sep; 22(9):1230-1239. PubMed ID: 34310904
[TBL] [Abstract][Full Text] [Related]
11. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
12. Beyond the Androgen Receptor: The Sequence, the Mutants, and New Avengers in the Treatment of Castrate-Resistant Metastatic Prostate Cancer.
Westaby D; Viscuse PV; Ravilla R; de la Maza MLDF; Hahn A; Sharp A; de Bono J; Aparicio A; Fleming MT
Am Soc Clin Oncol Educ Book; 2021 Jun; 41():e190-e202. PubMed ID: 34061561
[TBL] [Abstract][Full Text] [Related]
13. Plants and cervical cancer: an overview.
Wang SJ; Zheng CJ; Peng C; Zhang H; Jiang YP; Han T; Qin LP
Expert Opin Investig Drugs; 2013 Sep; 22(9):1133-56. PubMed ID: 23789984
[TBL] [Abstract][Full Text] [Related]
14. Interplay between orphan nuclear receptors and androgen receptor-dependent or-independent growth signalings in prostate cancer.
Wang Y; Gao W; Li Y; Chow ST; Xie W; Zhang X; Zhou J; Chan FL
Mol Aspects Med; 2021 Apr; 78():100921. PubMed ID: 33121737
[TBL] [Abstract][Full Text] [Related]
15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
16. Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer.
Msaouel P; Nandikolla G; Pneumaticos SG; Koutsilieris M
Expert Opin Investig Drugs; 2013 Nov; 22(11):1385-400. PubMed ID: 24024652
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
Yanagisawa T; Rajwa P; Kawada T; Mori K; Fukuokaya W; Petrov P; Quhal F; Laukhtina E; von Deimling M; Bianchi A; Majdoub M; Pradere B; Kramer G; Kimura T; Shariat SF
J Urol; 2023 Sep; 210(3):416-429. PubMed ID: 37339479
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
19. New insights into molecular signaling pathways and current advancements in prostate cancer diagnostics & therapeutics.
Thakur N; Quazi S; Naik B; Jha SK; Singh P
Front Oncol; 2023; 13():1193736. PubMed ID: 37664036
[TBL] [Abstract][Full Text] [Related]
20. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
Crawford ED; Schellhammer PF; McLeod DG; Moul JW; Higano CS; Shore N; Denis L; Iversen P; Eisenberger MA; Labrie F
J Urol; 2018 Nov; 200(5):956-966. PubMed ID: 29730201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
